Please ensure Javascript is enabled for purposes of website accessibility

Greenleaf named CEO of Mass. biotech

Peter Greenleaf, a respected figure in biotechnology circles with over 20 years of experience in the industry, has been named CEO of Waltham, Mass.-based Histogenics Corp.

Greenleaf’s most recent position was president of Gaithersburg-based MedImmune, the worldwide biologics arm of AstraZeneca.

He also was president of MedImmune Ventures, MedImmune’s venture capital arm, overseeing more than $300 million in investments in early-stage portfolio companies.

Greenleaf currently chairs the Maryland Venture Fund Authority.

Histogenics is a regenerative medicine company that combines cell therapy and tissue engineering technologies to develop innovative products primarily used for orthopedic tissue repair.